Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 20th International Conference on Neonatology and Perinatology Madrid, Spain.

Day 1 :

Keynote Forum

Ling-Qun Hu

Executive director of No Pain Labor & Delivery - Global Health Initiative , USA

Keynote: Impact of Neuraxial Labor Analgesia on Neonatal Outcomes
Neonatology 2017 International Conference Keynote Speaker Ling-Qun Hu photo

Dr. Hu graduated from Zhejiang University School of Medicine in 1984. He was an internist in China and a researcher in Canada. In 2001, after his residency training in USA, he became an anesthesiologist at Northwestern University Feinberg School of Medicine. He is the founder and executive director of No Pain Labor & Delivery - Global Health Initiative and the editor-in-chief of its journal. He has published three books as the author or associate-author and five books as a chief translator or associate-chief translator.  He has published 23 papers in reputable journals and serves as an editorial board member of three.


An education program, No Pain Labor & Delivery - Global Health Initiative (NPLD-GHI), was implemented at the Second Hospital of Wenzhou Medical College, China in 2010 to increase practice of neuraxial labor analgesia (NA). A two-phase impact study was conducted to assess the impact of increased NA on neonatal outcome.

In Phase I study, NA was utilized in the first stage of labor. Data was collected during three time periods: baseline (01/2009-06/2009, NA=0%), phase-in (07/2009-05/2010), and post-NPLD-GHI (06/2010-06/2011, NA~50%).  In Phase II study, NA was used in both first and second stages of labor,  and 2014 ACOG definition for arrest of labor was used. This phase collected data from 03/2014-05/2015. The initial 3 months of this period were considered baseline. The primary outcome was NICU admission rate, which was compared between pre- and post-interventions, for each study phase. Statistical significance was defined at p < 0.05.

The NA rate increased from 0% to ~50% of 15,415 deliveries after NPLD-GHI intervention (Table 1, Figure 1) in Phase I study. Our measured variables showed no significant changes. In Phase II study, improved rates of NICU admission, 7-day mortality, Apgar 0-3, antibiotics usage, and intubation from 10,414 deliveries were observed (Table 1, Figure 2) with better maternal outcomes.

            Our data indicate the improvement of neonatal outcomes with implementation of combined NA throughout two stages of labor and the 2014 ACOG definition for arrest of labor.

Table 1. Impact of Neuraxial Labor Analgesia on Neonatal Outcome


Phase I Study

Baseline (%)




95% CI







Total delivery






NICU admission

223 (8.2)

612 (8.2)



0.86, 1.16

Neonatal 7-day mortality

3 (1.1)

15 (2.0)



0.52, 6.30

Apgar 0-3 at 5 minutes

45 (1.6)

109 (1.5)




Cesarean delivery

1240 (46)

3112 (42)



0.33, 0.47

Neuraxial labor analgesia

0 (0)

2538 (47*)



116, 29680

Phase II Study

Pre- combined interventions (%)

Post-combined interventions (%)



95% CI







Total delivery






NICU admission

264 (14)

491 (5.7)



0.35, 0.46

Neonatal 7-day mortality

12 (0.6)

14 (0.2)



0.11, 0.55

Apgar 0-3 at 5 minutes

13 (0.7)

29 (0.3)



0.25, 0.93

Neonatal intubation

41 (2.2)

92 (1.1)



0.34, 0.70

Neonatal antibiotics usage

136 (7.3)

285 (3.3)



0.37, 0.55

Cesarean delivery

750 (40)

3067 (36)



0.84, 0.95

Neuraxial labor analgesia

519 (44)

3330 (57*)



1.19, 1.39

*Neuraxial labor analgesia rate = parturients with neuraxial labor analgesia / parturients with vaginal delivery or intrapartum cesarean delivery


Keynote Forum

Terence T Lao

The Chinese University of Hong Kong, Hong Kong

Keynote: Effect of neonatal immunization on vertical transmission of hepatitis B virus infection
Neonatology 2017 International Conference Keynote Speaker Terence T Lao photo

Terence Lao graduated MBBS from the University of Hong Kong, and obstained his MD in 2002. He received training in Obstetric Medicine at the Queen Charlotte’s Maternity Hospital, London, UK in 1983-4, and completed the fellowship programme in Maternal-Fetal Medicine at the University of Toronto in 1989-93. He is professor at the Department of Obstetrcs & Gynaecology, The Chinese University of Hong Kong. He has published 300+ papers in international journals and is a reviewer for 24 journals, and serves on the editorial board of three international journals. His major interest is in maternal medicine and high risk pregnancy.


Vertical transmission of the hepatitis B virus (HBV) is considered the major factor in maintinaing the high prevalence of HBV infection in endemic areas, and combined passive-active immunization has been introduced for more than three decades to prevent vertical transmission. Recently, maternal treatment with antiviral agents has been advocated to prevent vertical transmission, but no randomized studies have compared the efficacy of maternal antenatal treatment alone versus neonatal hepatitis B immunoglobulin (HBIg) injection alone in this regard. The safety of in-utero expsoure to antiviral agents to the long term health and development in the offspring is largely unknown, and the limited literature on maternal treatment appears to be associated with increased maternal postpartum flares and possibly adverse perinatal outcome. In the literature and in our experience, neonatal HBIg is safe and effective in preventing vertical transmission, and the relevant data will be presented. The pros and cons of maternal treatment in addition to the already implemented and established neonatal immunization for the sole purpose of preventing vertical transmission will be discussed, together with the implications on logistical and clinical management of pregnancy in women with chronic HBV infection.